SCHEDULE: J. Goldman & Co. Reports 5.1% Stake in Eagle Pharma

J. Goldman & Co. LP, along with its affiliates, has reported a passive beneficial ownership of 5.1% in Eagle Pharmaceuticals, Inc. common stock.

Summary

• J. Goldman & Co. LP, J. Goldman Capital Management, Inc., and Jay G. Goldman collectively beneficially own 667,108 shares of Eagle Pharmaceuticals, Inc. Common Stock.
• This represents 5.1% of the outstanding class of securities.
• The reporting persons hold shared voting power and shared dispositive power over all 667,108 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a standard beneficial ownership disclosure (Schedule 13G) and does not contain operational or financial performance data to assess positive or negative sentiment beyond the fact of a significant investor holding a stake.

Positives

• The disclosure of a significant stake (5.1%) by an institutional investor like J. Goldman & Co. LP may indicate investor confidence in Eagle Pharmaceuticals, Inc.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership and does not provide specific insights into broader industry trends or competitive landscape for the pharmaceutical sector.

Stakeholder Impact

• Shareholders may view the disclosure of a new significant institutional investor as a positive signal, potentially influencing market perception and share price.

Key Dates

Keywords

Eagle Pharmaceuticals, Common Stock, Schedule 13G, Beneficial Ownership, J. Goldman & Co., Investment, Pharmaceuticals